CXCR4 and neoplasm: Our previous results, which demonstrated that OVV-CXCR4-A-Fc treatment of mice with orthotropic breast and ovarian tumors exhibits increased efficacy over oncolysis alone [15,16,27], prompted us to examine the effect of the armed oncolytic virotherapy on induction of protective immune responses with DC vaccines presenting tumor-associated antigens from murine neuroblastoma cells (NXS2).